Myeloma sleeper agent in myeloid disguise

Sleeper effects.

Early experience preserves and refines many capabilities that emerge prenatally. Here we describe another role that it plays -- establishing the neural substrate for capabilities that emerge at a much later point in development. The evidence comes from sleeper effects: permanent deficits when early experience was absent in capabilities that normally emerge long after birth. We provide evidence ...

Therapy-Related Myeloid Malignancies in Myeloma

Therapy related myeloid malignancies are an increasingly recognized treatment complication in patients undergoing therapy for multiple myeloma. The main predisposing factors are the alkylating agents, topoisomerase II inhibitors and radiotherapy, but recently questions have been raised regarding the immunomodulatory agent lenalidomide. Little is known about the new antimyeloma agents in the con...

Dualism in Disguise

ELT: A Trojan Horse in Disguise?

Many people believe that language teaching is a neutral practice. However, this belief is not without its own opponents. To many scholars, teaching languages cannot be devoid of teaching cultural values of the target language, which tacitly aims at denigrating cultural values of the community of the learners who are learning it. The ultimate purpose of such cultural oppression, according to the...

Carfilzomib: a novel agent for multiple myeloma.

OBJECTIVES Carfilzomib is a new agent for the treatment of relapsed and refractory multiple myeloma (MM). This article presents a comprehensive overview of the pharmacokinetics, pharmacodynamics, dosing schedule, safety, efficacy, preparation and administration of carfilzomib, and its role in treating MM patients. KEY FINDINGS Carfilzomib is a selective proteasome inhibitor that differs struc...